12:00 AM
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Cabozantinib: Phase II started

Exelixis began an open-label, North American Phase II trial to compare oral cabozantinib in combination with abiraterone and prednisone vs. abiraterone and prednisone alone in 280 chemotherapy-naïve patients with CRPC who have bone metastases. Patients will receive 20 or 40 mg cabozantinib once daily or a 40 mg dose every other day. Exelixis markets cabozantinib as Cometriq in the U.S. to treat progressive, metastatic medullary thyroid cancer (MTC). Cometriq is under review for MTC in the EU, where it has...

Read the full 379 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >